-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on GoodRx Holdings, Lowers Price Target to $5

Benzinga·05/09/2025 18:02:38
Listen to the news
Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $6 to $5.